Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors
: meta-analysis of randomised controlled trials including 117,411 patients.
It is therefore unlikely that CETP inhibitors
will undergo further clinical development.
The most recent class of HDL-C--raising drugs that has been investigated, but so far has not shown a clinical benefit, is CETP inhibitors
. CETP inhibitors
act to increase HDL-C concentrations by preventing the CETP-catalyzed exchange of TGs in apoB-containing lipoproteins for HDL cholesteryl esters.
Pharmaceutical CETP inhibitors
such as Torcetrapib  and Dalcetrapib  have been shown to raise HDL-C levels effectively, but research into their clinical efficacy was unfortunately terminated due to off-target effect or lack of clinical benefit.
Niacin, fibrates and investigational drugs called CETP inhibitors
have been tested in clinical trials to determine if the HDL-raising properties of these drugs would further reduce cardiac events.
In past reports, the only other CETP inhibitors
to complete phase III trials either showed no incremental benefit like evacetrapib, which happened with dalcetrapib (N Engl J Med.
The decision is also the latest disappointment for this class of drags, known as CETP inhibitors
, which can raise the levels of so-called good cholesterol while lowering the levels of bad cholesterol.
. The cholesteryl ester transfer protein inhibitors torcetrapib and dalcetrapib flamed out in clinical trials because of safety concerns and lack of clinical benefit.
Current status of CETP inhibitors
in the treatment of hyperlipidemia: an update.
These findings point the way to the design of safer, more effective next generation CETP inhibitors
that could help prevent the development of heart disease.
Medicines called CETP inhibitors
that mimic the effect of the gene variation in the study are under development by Merck & Co.